An observational study in ARDS, Human, sponsored by Hvidovre University Hospital. Recruiting at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.
Sponsored by Hvidovre University Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Respiratory Distress Syndrome with a site in Denmark — 3 open to participants now, 3 under way, 1 of them phase 3. Respiratory Distress Syndrome · Denmark.
Among the 12 studies in Respiratory Distress Syndrome with a site in Denmark, this one is the only one that started in 2023, is one of 5 observational ones, and was the 12th registered.
1,389 studies on the registry are indexed under Respiratory Distress Syndrome; 281 are open to participants now.
Browse Respiratory Distress Syndrome studies →3 of the 12 studies in Respiratory Distress Syndrome with a site in Denmark are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Denmark, United States, Argentina and 36 more countries
Ages 18+
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Sites in Denmark, Belgium, China and 5 more countries
Ages 18–100
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 196 Respiratory Distress Syndrome studies recruiting now, 116 (59%) set no upper age limit and 50 (26%) stop at 75 or younger; 52 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2023.
This study's planned enrollment of 40 is below the median of 100 across 476 observational studies indexed under Respiratory Distress Syndrome.
Median enrollment 538 across the 7 interventional studies, 68 across the 5 observational. Of the 7 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 12 have an industry lead sponsor. The 9 most frequent:
Hvidovre University Hospital is the lead sponsor of 299 studies on the registry; 20 are open to participants now.
Hvidovre University Hospital has 1 study filed under Respiratory Distress Syndrome — fewer than ten, so there is no comparison to draw.
2 of the studies in Respiratory Distress Syndrome with a site in Denmark that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT05492344Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Personalized Mechanical Ventilation Guided by UltraSound in Patients With Acute Respiratory Distress Syndrome | 2027-08-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 12 studies in Respiratory Distress Syndrome with a site in Denmark, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The overall aim is to compare the composition and spatial heterogeneity of the following in critically ill intensive care unit (ICU) patients: i) immune cell populations and their activation patterns, ii) the surrounding cytokine-chemokine milieu, including trans-compartmental fluxes of these mediators between the lung and bloodstream, and iii) the lung microbiome.
Main hypotheses:
Background Pulmonary hyperinflammation with neutrocyte and macrophage invasion and T cell depletion are common features of the acute respiratory distress syndrome (ARDS), but it remains to be elucidated whether the T cells in the lungs of patients with ARDS are hyperactivated and/or exhausted, and to which extent this contributes to neutrocyte invasion and thus lung tissue destruction. Furthermore, the pulmonary microbiome has shown a reduction in diversity and interactions in ARDS, which may be important for normal T cell function. At present, immune cell-microbiome interactions and their relation to disease severity and progression have not yet been studied in ARDS.
Overall design In 20 mechanically ventilated patients with none-to-mild and 20 with moderate-to-severe non-COVID-19 ARDS according to the Berlin definition an endotracheal aspirate and BAL fluid (BALF) from separate lung segments will be obtained. Furthermore, an oral and nasal swab and blood samples will be collected. This will be done within 72 hours after intubation, and again after 7-10 days if the patient is still intubated.
Patient's electronic health record The following is obtained after inclusion: diagnosis codes and medication (type and dosage, including vasopressors and sedatives), and smoking history (current/previous/never smoker; pack years); admission time; blood pressure, heart rhythm and heart rate, temperature, ventilator settings, supportive care (dialysis, ECMO), blood tests results at admission and on the study days (blood cell counts, coagulation parameters, renal, liver, and electrolyte panel; arterial and mixed venous blood gases); clinical scores at admission and on the study days (SAPS3, APACHE II, SOFA), death within 30 days
Blood sampling Arterial blood samples are drawn from the patient's invasive arterial catheter (inserted at ICU admission for clinical purposes: for continuous invasive blood pressure monitoring and repeated arterial blood gas collection) immediately before BALF collection.
Bronchoscopy with BALF collection This procedure is performed in a standardized fashion according to current clinical guidelines. Immediately prior to the procedure, an oral swab, nasal swab and an endotracheal aspirate (ETA) are obtained. FIO2 is then increased to 1.0, and the bronchoscopy procedure is performed using a disposable videoscope with an outer diameter of 5.0 mm). Three successive 50-ml aliquots of prewarmed (37°C) isotonic saline are instilled in the medial segment of the right middle lobe, aspirated immediately with low negative suction pressure (\< 100 cm H2O), and pooled into a sterile glass container on ice to obtain a BALF specimen.
Afterwards a mini-BAL is performed in the upper and lower lobe of the right lung with a single installation of 20 ml isotonic saline in each lobe with immediately aspiration into a sterile container.
Measurements The composition of the immune cell population, as well as the function and differentiation of various cell lines will be investigated by single-cell RNA sequencing (scRNA-seq) on selected immune cells from BALF, ETA, and blood, and this will be supplemented by bulk RNA sequencing with sample barcoding and multiplexing, giving a detailed expression pattern of all samples.
The composition microbiome in BALF, ETA, and oral swabs will be assessed by targeted amplicon sequencing of the hyper-variable regions 1 through 3 of the 16S subunit of ribosomal RNA gene for bacteria.
Statistical analyses will be performed using R statistical software version 4.1.1 (R Project for Statistical Computing) within RStudio statistical software version 1.4.1717 (RStudio), and p\<0.05 considered statistically significant. Inspection of normality and variance homogeneity will be done by creating qq-plots and histograms. The statistical inference tools SPIEC-EASI and HeatMaps will be used, and based on correlational analyses, principal component analyses, including non-hierarchal cluster analysis, will be applied to identify traits in the two groups.
Mechanically ventilated adult ICU patients at Hvidovre University Hospital
Inclusion Criteria:
Inclusion criteria - none-to-mild ARDS
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Procedure: Bronchoalveolar lavage
Procedure: Bronchoalveolar lavage
Bronchoalveolar lavage in the middle lobe of the right lung and a mini-bronchoalveolar lavage in the upper and lower lobe of the right lung
Lung microbiome
16S ribosomal RNA (rRNA) and 18S rRNA PCR for bacterial or fungal pathogen identification in bronchoalveolar lavage flui
Time frame: Day 0 (subsequent to study inclusion in the ICU)
Lymphocyte populations
Cell populations and subpopulations evaluated by 10 colored flow cytometry (B cells, T cells, TCR subsets, Tregs/Th17, dendritic cells, myeloid cells and neutrophils) in bronchoalveolar lavage fluid and blood
Time frame: Day 0 (subsequent to study inclusion in the ICU)
Cell differential counts and cytomorphological analyses of BALF
Time frame: Day 0 (subsequent to study inclusion in the ICU)
Trans-compartmental fluxes
(calculated from plasma- and urea-adjusted BAL)
Time frame: Day 0 (subsequent to study inclusion in the ICU)
Auto-antibodies against tI-IFNs in blood
Measured in bronchoalveolarlavage fluid
Time frame: Day 0 (subsequent to study inclusion in the ICU)
White blood cells counts
Total white blood cells, neutrocytes, lymphocytes, and monocytes in bronchoalveolar lavage fluid and blood
Time frame: Day 0 (subsequent to study inclusion in the ICU)
Cytokines
Multiplex assay for measuring cytokines in bronchoalveolar lavage fluid and plasma (e.g. IL-1-beta, IL-1RA, IL-2, IL-6, IL-8, IL-10, IL-17, IL-18, IL-33, IL-35, TGF-beta, TNF-alpha, HMGB1)
Time frame: Day 0 (subsequent to study inclusion in the ICU)
Number and characterizations of respiratory pathogens
Respiratory filmarray PCR for testing for number of pathogens
Time frame: Day 0 (subsequent to study inclusion in the ICU)
Number and characterizations of microorganisms
Growth of pathogenic microorganisms in body fluids (e.g. urine, blood, bronchoalveolar lavage fluid) in microbiological assays
Time frame: Up to 12 weeks
Plan to share: Undecided
No publications or documents are linked to this record.
Started Mar 2023 (actual). Primary completion is estimated for Nov 2028, 68 months after the start.
Of 228 non-industry observational studies under Respiratory Distress Syndrome, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's planned 68 months is above that.
Counting every sponsor, half of 234 studies reached it within 24 months; a quarter within 12 and three quarters within 49.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Respiratory Distress Syndrome →
Hvidovre University Hospital →